Fatal Intoxication Involving 3-MeO-PCP: A Case Report and Validated Method.
Erica L. Bakota, Crystal Arndt, A. Romoser, Stephen K Wilson
Journal of Analytical Toxicology September 1, 2016 DOI: 10.1093/jat/bkw056 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Case report Peer reviewed |
|---|---|
| Sample size | 1 |
| Population | A 29-year-old male decedent with a history of illicit drug use |
| Topics | 5-MeO-DMT |
| Key findings | The decedent's blood contained 139 ± 41 µg/L of 3-MeO-PCP, identified via validated LC-MS-MS, along with diphenhydramine and amphetamine. The cause of death was determined to be combined toxicity of these substances, with the manner certified as an accident. |
Abstract
We present in this case report a validated method for accurate quantitative analysis of 3-methoxy phencyclidine (3-MeO-PCP) to determine postmortem blood concentrations of this PCP analog. A 29-year-old male with a history of illicit drug use was found unresponsive in his bed with a bag of white powder next to him. Resuscitation efforts were unsuccessful and the individual was pronounced dead 9 minutes after arrival to the hospital. Initial ELISA screening suggested the presence of PCP in the decedent's blood. However, confirmatory testing revealed no detectable PCP. Instead, a large peak corresponding to a m/z 274.218 species with retention time similar to PCP was present on a LC-TOF-MS drug screen, suggesting a possible PCP analog. This mass corresponds specifically to a methoxy-PCP analog, several of which are available for purchase online. Standards for 3-MeO-PCP and 4-MeO-PCP were obtained and injected on the same instrument. Although the 3- and 4-MeO-PCP analogs have identical masses and retention times, they are still distinguishable through their mass spectra. The peak from the decedent's sample matched both the mass spectrum and the retention time of 3-MeO-PCP. A quantitative LC-MS-MS method was subsequently developed and validated for casework. Analysis using this method revealed a concentration of 139 ± 41 µg/L 3-MeO-PCP in the decedent's blood. Diphenhydramine (4.1 ± 0.7 mg/L), marijuana metabolite (presumptive positive, confirmation not performed) and a small amount of amphetamine (<0.10 mg/L) were also found in the decedent's blood. The cause of death was determined to be combined 3-MeO-PCP, diphenhydramine and amphetamine toxicity. The manner of death was certified as an accident.
Citations in the library
Cited by 18
- Designer drugs: mechanism of action and adverse effects Archives of Toxicology April 1, 2020
- Reports of Adverse Events Associated with Use of Novel Psychoactive Substances, 2017–2020: A Review Journal of Analytical Toxicology April 20, 2022
- No prescription? No problem: A qualitative study investigating self-medication with novel psychoactive substances (NPS). International Journal of Drug Policy August 1, 2023
- The First Fatal Intoxication with 3-MeO-PCP in the UK and a Review of the Literature. Journal of Analytical Toxicology May 20, 2022
- Intoxication by 3-MeO-PCP and O-desmethyltramadol: an unusual NPS mix. International Journal of Legal Medicine September 1, 2022
and 13 more in the library
Cites 9
- Clinical toxicology of newer recreational drugs Clinical Toxicology October 1, 2011
- From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs. Drug Testing and Analysis 2014
- Phenomenon of new drugs on the Internet: the case of ketamine derivative methoxetamine Human Psychopharmacology: Clinical and Experimental March 1, 2012
- The ketamine analogue methoxetamine and 3- and 4-methoxy analogues of phencyclidine are high affinity and selective ligands for the glutamate NMDA receptor. PLoS One June 14, 2016
- A Fatality Related to Two Novel Hallucinogenic Compounds: 4-Methoxyphencyclidine and 4-Hydroxy-N-methyl-N-ethyltryptamine Journal of Analytical Toxicology August 10, 2015
and 4 more in the library